Navigation Links
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:10/30/2008

isks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007, and its Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2008.

ISTA Pharmaceuticals, Inc.

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenue

Product sales, net $21,604 $15,796 $54,749 $39,497

License revenue 69 69 208 208

Total revenue 21,673 15,865 54,957 39,705

Cost of products sold 5,806 4,197 14,761 10,417

Gross profit margin 15,867 11,668
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
2. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
3. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Watson Pharmaceuticals Reports Third Quarter 2008 Results
6. Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
7. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
10. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
11. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... Overeating is common during the holidays, but there are strategies ... "Don,t arrive at a party hungry. It may seem ... attending a party, but deprivation leads to hunger, and hunger ... Hospital in Mount Kisco, N.Y., said in a hospital news ... and even to have a snack before attending a party ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... scoliosis needs treatment, they often try bracing first. If that ... backs with spinal fusion later on. These children face the ... chests may be stiff for life. New research from ... convention and may lead doctors to choose to tweak an ...
... ... Clinical Trial Matching Service Adds New "Trial Alert" and "SecureCONNECT" Web 2.0 Components, ... ... matching service dedicated exclusively to breast cancer--BreastCancerTrials.org--is now upgraded with new features, greatly ...
... Actresses and mother-daughter pair Blythe Danner and Gwyneth ... (EIF) public service announcement that celebrates the health benefits of volunteerism. ... major broadcast networks - ABC, CBS, FOX and NBC - will ... iParticipate national initiative to promote service and volunteering. , The ...
... WILMINGTON, Delaware, September 30 ... by,MarketsandMarkets ( http://www.marketsandmarkets.com ), the global market for,neurostimulation products ... and,expected to reach $10.2 billion by 2014, driven by ... of venture,capital in the industry. , ...
... GAITHERSBURG, Md. and WASHINGTON, Sept. 30 On Tuesday, ... , one of America,s largest co-payment assistance organizations, hosted ... growing crisis of the underinsured and the related challenges ... http://www.newscom.com/cgi-bin/prnh/20090930/NY84016LOGO ) , Held at ...
... Networks(TM), the leader in next-generation firewalls, today announced that it ... 2009, taking place Oct. 5 - 6 in Santa Clara, ... Networks, will present "What,s on Your Network? Technology Options for ... Oct. 6. Information about the conference can be found at ...
Cached Medicine News:Health News:Where surgery was the standard, casting may be the future 2Health News:UCSF Announces Expanded BreastCancerTrials.org Website 2Health News:UCSF Announces Expanded BreastCancerTrials.org Website 3Health News:UCSF Announces Expanded BreastCancerTrials.org Website 4Health News:UCSF Announces Expanded BreastCancerTrials.org Website 5Health News:UCSF Announces Expanded BreastCancerTrials.org Website 6Health News:Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 2Health News:Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 3Health News:MarketsandMarkets: Global Neurostimulation Market Worth US$10.2 Billion by 2014 2Health News:MarketsandMarkets: Global Neurostimulation Market Worth US$10.2 Billion by 2014 3Health News:HealthWell Foundation(R) Gathers Leading Health Care Stakeholders to Discuss Crisis of the Underinsured 2Health News:HealthWell Foundation(R) Gathers Leading Health Care Stakeholders to Discuss Crisis of the Underinsured 3Health News:Palo Alto Networks to Present at the Computer Forensics Show 2009 2
(Date:12/24/2014)... Kinex Pharmaceuticals announced today that the first ... Cancer Institute. KX2-361 (KX02), a dual src/pre-tubulin ... potent inhibitory activity against a broad panel of brain ... Temozolomide (T98G), the most widely used chemotherapy for the ... mouse model, KX2-361 consistently clears brain tumors after 4 ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing ... Chief Technology Officer, will present at the Sidoti & ... on Thursday, November 10, 2011 at 1:20 p.m. ET. ... New York Hotel in New York City. ...
... Nov. 7, 2011 Reportlinker.com ... research report is available in ... Implantable Cardioverter Defibrillators and Cardiac ... Analysis, Competitive Landscape and Market ...
Cached Medicine Technology:Abaxis, Inc. to Present at Sidoti & Company's New York II Emerging Growth Institutional Investor Forum 2Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 14Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 15Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 16
... helps you deliver unmatched performance through patient-focused ... the most complete anesthesia solution developed, putting ... - at your fingertips., ,The Aisys ... legacy of anesthesia delivery and patient monitoring ...
... Mesh LP is a super-light polypropylene mesh ... body reaction is reduced considerably. Optilene Mesh ... all open hernia repair procedures. It perfectly ... flexibility Optilene Mesh LP adapts to the ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
... is a lightweight polypropylene mesh which ... reduced,foreign body reaction. The softer, microfilament ... perfectly conforms to,anatomical structures. Due to ... adapts to the movements of the ...
Medicine Products: